Kopran Limited · NSE:KOPRAN
Kopran — Q1 FY2024-25 Earnings Presentation
21 slides from Kopran's earnings presentation, Aug 1, 2024
Slide 1: Corporate Presentation Q1 FY 2024-25
CORPORATE PRESENTATION Q1 FY 2024-25
Slide 2: This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not
This quarterly investor presentation has been prepared by Kopran Limited (‘Kopran’) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not
Slide 3: Performance
PERFORMANCE • Financial Highlights • Operational Performance • API • Formulation
Slide 4: Financial Highlights
PARTICULARS Q1 FY 2024-25 Q1 FY 2023-24 Q4 FY 2023-24 Revenue from Operations 13,944 11,700 18,608 Other Income ** 263 239 967 EBITDA* 1,816 631 2,169 Finance Costs 218 183 259 Depreciation 387 326 359 Tax Expenses 364 84 656 Net Profit 1,110 277 1,862 EBITDA Margin 13.03% 5.39% 11.66% PARTICULARS Q
Slide 5: Operational Performance
OPERATIONAL PERFORMANCE
Slide 6: APIs Operational Highlights: Segment-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS SEGMENT-WISE REVENUE MIX Q1 FY 2024-25 (Rs. In Lakhs) FY 2023-24 (Rs. In Lakhs) 474 102 17 932 939 107 Anti- Diabetic 3245 Anti Diabetic Anti- Infective 162 Anti Infective 11 181 Antibiotic-Urological Antibiotic-Urological 1381 Anti-Hypertensive 4393 Anti-Hyperetensive Ne
Slide 7: APIs Operational Highlights: Market-wise Revenue Mix
APIs OPERATIONAL HIGHLIGHTS MARKET-WISE REVENUE MIX Q1 FY 2024-25 (Rs. In Lakhs) FY 2023-24 (Rs. In Lakhs) Export Sales Export Sales Local Sales Local Sales 4561 15228 4429 14967 Total Rs. 8,990 Lakhs Total Rs. 33,288 Lakhs
Slide 8: Formulations Operational Highlights: Region-wise Sales Break-up
Formulations OPERATIONAL HIGHLIGHTS REGION-WISE SALES BREAK-UP Q1 FY 2024-25 (Rs. In Lakhs) FY 2023-24 (Rs. In Lakhs) 219 1865 Africa 508 Africa 793 1460 8873 CANADA CANADA Latem Latem Middle East and North Africa Middle East and North Africa 60 73 South Africa South Africa 208 569 Southeast Asia 21
Slide 9: Formulations Operational Highlights: Product-wise Revenue Mix
Formulations OPERATIONAL HIGHLIGHTS PRODUCT-WISE REVENUE MIX Q1 FY 2024-25 (Rs. In Lakhs) FY 2023-24 (Rs. In Lakhs) 1513 Non Pen Plant Non Pen Plant Pen Plant Pen Plant 11955 3370 15901 Total Rs. 4,883 Lakhs Total Rs. 27,856 Lakhs
Slide 10: Company Overview
Company Overview • About Us • Business Overview – API • Business Overview – Formulations • Driving Sustainable Growth
Slide 11: A Global Pharmaceutical Company
A GLOBAL PHARMACEUTICAL COMPANY An integrated Pharmaceutical Company, committed to supplying International 50+ Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally. Nations - Export Reach State-of-the-art manufacturing facilities and products with various accreditations and app
Slide 12: API Vertical
API API DEDICATED AND VERSATILE PRODUCT VERTICAL FACILITIES FOR SEGMENT Development, manufacturing and Atenolol Anti-hypertensive sale of diverse APIs and Advanced Macrolide Intermediates Cephalosporins - Non-Sterile & Sterile Neuromodulator One of the leaders in Atenolol Macrolides
Slide 13: Formulations Vertical: Product Segments
FORMULATIONS PRODUCT SEGMENTS FORMULATIONS VERTICAL Development and manufacturing of oral solid dosages and dry powder formulations for both Penicillin- and Non-Penicillin-based drugs PENICILLIN-BASED NON-PENICILLIN FINISHED ORAL BASED FINISHED Catering 100% export markets of both Regulated and
Slide 14: Strategic Imperatives
STRATEGIC IMPERATIVES GROWTH AND SUSTAINABILITY COST LEADERSHIP Focus on R&D to develop niche, Development of intermediates for APIs high-value/high-volume APIs and intermediates Reducing dependence on China to move towards self sufficiency Capacity expansion Optimising operational cost
Slide 15: Regulatory Compliance
REGULATORY COMPLIANCE OFFERING BEST-IN-CLASS QUALITY THROUGH STRICT COMPLIANCE The Company maintains highest global regulatory standards FORMULATIONS ACCREDITATIONS of manufacturing and quality at its all plants API ACCREDITATIONS Approved by 15 countries including MHRA (UK), SAPHRA South The plant
Slide 16: Financial Performance
FINANCIAL <—) PERFORMANCE Kopran
Slide 17: Snapshot
SNAPSHOT SALES/OTHER INCOME (₹ LAKHS) EBITDA * (₹ LAKHS) 8,739 8,178 62,920 7,441 55,405 50,980 48,813 5,180 4,696 36,013 1,816 14,206 2019-20 2020-21 2021-22 2022-23 2023-24 Jun-24 2019-20 2020-21 2021-22 2022-23 2023-24 Jun-24 891 859 6,161 6,103 5,096 624 608 512 2,723 2,120 218 1,110 2019-20 202
Slide 18: Building Shareholder Value Year on Year
BUILDING SHAREHOLDER VALUE YEAR ON YEAR EBITDA ( ₹ Lakhs) RoE ( % ) RoCE ( % ) 28.3 8,739 25.3 8,178 7,441 22.4 20.1 5,180 14.5 14.1 4,996 11.8 11 11.5 8.3 8.9 6.3 1,816 2019-20 2020-21 2021-22 2022-23 2023-24 Jun-24 2019-20 2020-21 2021-22 2022-23 2023-24 Q1 - Return on Networth/Equity - Return on
Slide 19: Financial Summary (Rs. Lakhs)
(Rs. Lakhs) PARTICULARS Q1 2025 FY 2023-24 FY 2022-23 FY 2021-22 FY 2020-21 FY 2019-20 Equity share capital 4,821 4,821 4,821 4,821 4,325 4,325 Other equity 45,418 44,303 39,104 37,796 20,178 14,643 Networth 50,239 49,125 43,925 42,617 24,503 18,968 Fixed Assets(net) 29,114 27,830 23,457 18,623 15,5
Slide 20: Board of Directors
BOARD OF DIRECTORS MR. SURENDRA SOMANI MR. ADARSH RAJENDRA SOMANI MRS. MAMTA BIYANI MR. NARAYAN ATAL EXECUTIVE VICE CHAIRMAN DIRECTOR INDEPENDENT DIRECTOR INDEPENDENT DIRECTOR DR. SIDDHAN SUBRAMANIAN DR. SUNITA BANERJI MR. SUSHEEL SOMANI MR. VARUN SURENDRA SOMANI INDEPENDENT DIRECTOR INDEPENDENT DIR
Slide 21: About Kopran Limited
ABOUT KOPRAN LIMITED: Kopran Limited is an integrated Pharmaceutical Company, committed to manufacturing and supplying International Quality Formulations and APIs worldwide. Kopran's manufacturing facilities and products have accreditations across all the continents. Research & Development for New P